Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 49.6% in February

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 84,500 shares, a decline of 49.6% from the February 13th total of 167,500 shares. Based on an average daily volume of 432,500 shares, the days-to-cover ratio is presently 0.2 days. Approximately 3.1% of the shares of the stock are short sold.

Institutional Trading of Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP bought a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics at the end of the most recent quarter. Hedge funds and other institutional investors own 6.17% of the company’s stock.

Theriva Biologics Stock Performance

Shares of NYSEAMERICAN:TOVX traded up $0.04 on Friday, hitting $1.15. The company had a trading volume of 38,411 shares, compared to its average volume of 155,790. Theriva Biologics has a 52-week low of $1.03 and a 52-week high of $17.11. The business has a 50 day moving average of $1.47. The firm has a market capitalization of $3.21 million, a P/E ratio of -0.03 and a beta of 1.22.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.